keyword
MENU ▼
Read by QxMD icon Read
search

Cancer chemotherapy

keyword
https://www.readbyqxmd.com/read/28822335/specificity-protein-1-modulated-superoxide-dismutase-2-enhances-temozolomide-resistance-in-glioblastoma-which-is-independent-of-o-6-methylguanine-dna-methyltransferase
#1
Kwang-Yu Chang, Tsung-I Hsu, Che-Chia Hsu, Shan-Yin Tsai, Jr-Jiun Liu, Shao-Wen Chou, Ming-Sheng Liu, Jing-Ping Liou, Chiung-Yuan Ko, Kai-Yun Chen, Jan-Jong Hung, Wen-Chang Chang, Cheng-Keng Chuang, Tzu-Jen Kao, Jian-Ying Chuang
Acquisition of temozolomide (TMZ) resistance is a major factor leading to the failure of glioblastoma (GBM) treatment. The exact mechanism by which GBM evades TMZ toxicity is not always related to the expression of the DNA repair enzyme O(6)-methylguanine-DNA methyltransferase (MGMT), and so remains unclear. In this study, TMZ-resistant variants derived from MGMT-negative GBM clinical samples and cell lines were studied, revealing there to be increased specificity protein 1 (Sp1) expression associated with reduced reactive oxygen species (ROS) accumulation following TMZ treatment...
August 12, 2017: Redox Biology
https://www.readbyqxmd.com/read/28822078/prognostic-implication-of-the-primary-tumor-location-in-early-stage-breast-cancer-focus-on-lower-inner-zone
#2
Jiqiao Yang, Shenli Tang, Yuting Zhou, Juanjuan Qiu, Juying Zhang, Sui Zhu, Qing Lv
BACKGROUND: The aim of this study was to investigate the prognostic significance of tumor location of lower inner zone (LIZ) on the survival of patients with early-stage breast cancer. METHODS: We retrospectively identified 961 breast cancer patients from Jan 2000 to Apr 2016 from hospital database. We evaluated overall survival (OS) and disease-free survival (DFS) in patients with tumors in and outside LIZ. Subgroup analyses were performed according to clinicopathological characteristics and treatment strategies...
August 18, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28822007/brca1-like-profile-is-not-significantly-associated-with-survival-benefit-of-non-myeloablative-intensified-chemotherapy-in-the-gain-randomized-controlled-trial
#3
A G J van Rossum, P C Schouten, K E Weber, V Nekljudova, C Denkert, C Solbach, C H Köhne, C Thomssen, H Forstbauer, G Hoffmann, A Kohls, S Schmatloch, C Schem, G von Minckwitz, T Karn, V J Möbus, S C Linn, S Loibl, F Marmé
PURPOSE: The BRCA1-like profile identifies tumors with a defect in homologous recombination due to inactivation of BRCA1. This profile has been shown to predict which stage III breast cancer patients benefit from myeloablative, DNA double-strand-break-inducing chemotherapy. We tested the predictive potential of the BRCA1-like profile for adjuvant non-myeloablative, intensified dose-dense chemotherapy in the GAIN trial. METHODS: Lymph node positive breast cancer patients were randomized to 3 × 3 dose-dense cycles of intensified epirubicin, paclitaxel, and cyclophosphamide (ETC) or 4 cycles concurrent epirubicin and cyclophosphamide followed by 10 cycles of weekly paclitaxel combined with 4 cycles capecitabine (EC-TX)...
August 18, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28821959/identifying-cisplatin-induced-kidney-damage-in-paediatric-oncology-patients
#4
REVIEW
Chris D Barton, Barry Pizer, Caroline Jones, Louise Oni, Munir Pirmohamed, Daniel B Hawcutt
Cisplatin is one chemotherapeutic agent used to treat childhood cancer in numerous treatment protocols, including as a single agent. It is likely to remain in clinical use over the long term. However, cisplatin-related toxicities, including neurotoxicity and nephrotoxicity, are common, affecting treatment, day-to-day life and survival of such children. With one in 700 young adults having survived childhood cancer, patients who have completed chemotherapy that includes cisplatin can experience long-term morbidity due to treatment-related adverse reactions...
August 18, 2017: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
https://www.readbyqxmd.com/read/28821938/depth-of-response-predicts-the-clinical-outcome-of-advanced-her2-positive-gastric-cancer-to-trastuzumab-based-first-line-chemotherapy
#5
Shigenori Kadowaki, Toshiki Masuishi, Tetsuya Eto, Yukiya Narita, Hiroya Taniguchi, Takashi Ura, Masashi Ando, Masahiro Tajika, Yasumasa Niwa, Yasushi Yatabe, Kei Muro
PURPOSE: Accumulating evidence suggests that response-related parameters such as depth of response (DpR) might be associated with survival in colorectal cancer, which has not been shown in gastric cancer. This study aimed to evaluate whether DpR was associated with clinical outcomes in HER2-positive AGC patients treated with trastuzumab-based chemotherapy. METHODS: Fifty-seven HER2-positive AGC patients who were treated with trastuzumab in combination with fluoropyrimidines plus cisplatin therapy as first-line treatment were retrospectively enrolled...
August 18, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28821822/bladder-cancer-treatment-response-assessment-in-ct-using-radiomics-with-deep-learning
#6
Kenny H Cha, Lubomir Hadjiiski, Heang-Ping Chan, Alon Z Weizer, Ajjai Alva, Richard H Cohan, Elaine M Caoili, Chintana Paramagul, Ravi K Samala
Cross-sectional X-ray imaging has become the standard for staging most solid organ malignancies. However, for some malignancies such as urinary bladder cancer, the ability to accurately assess local extent of the disease and understand response to systemic chemotherapy is limited with current imaging approaches. In this study, we explored the feasibility that radiomics-based predictive models using pre- and post-treatment computed tomography (CT) images might be able to distinguish between bladder cancers with and without complete chemotherapy responses...
August 18, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28821817/high-mrna-expression-level-of-il-6r-was-associated-with-better-prognosis-for-patients-with-ovarian-cancer-a-pooled-meta-analysis
#7
Qu Chen, Bin Xu, Lei Lan, Da Yang, Min Yang, Jingting Jiang, Binfeng Lu, Yueping Shen
Interleukin-6 acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine. IL-6/IL-6R signaling pathway, in particular, has been proposed to be a pivotal cytokine promoting ovarian cancer progression. This study aimed to elucidate potential clinical and biological function of IL-6R mRNA expression in ovarian cancer. We used the keywords "ovarian cancer" and searched through GEO database and finally a total of 7 studies together with TCGA database were incorporated in this analysis. We used Cutoff Finder to determine a cutoff point and stratified patients into two groups and found that high-expression of IL-6R mRNA in tumor tissues was a positive prognostic factor for overall survival...
August 18, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28821631/6-methoxyethylamino-numonafide-inhibits-hepatocellular-carcinoma-xenograft-growth-as-a-single-agent-and-in-combination-with-sorafenib
#8
Yanning Liu, Guohua Lou, John T Norton, Chen Wang, Irawati Kandela, Shuai Tang, Nathaniel I Shank, Pankaj Gupta, Min Huang, Michael J Avram, Richard Green, Andrew Mazar, Daniel Appella, Zhi Chen, Sui Huang
Hepatocellular carcinoma (HCC) is the third leading form of cancer worldwide, and its incidence is increasing rapidly in the United States, tripling over the past 3 decades. The current chemotherapeutic strategies against localized and metastatic HCC are ineffective. Here we report that 6-methoxyethylamino-numonafide (MEAN) is a potent growth inhibitor of murine xenografts of 2 human HCC cell lines. At the same dose and with the same treatment strategies, MEAN was more efficacious in inhibiting tumor growth in mice than sorafenib, the only approved drug for HCC...
August 17, 2017: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://www.readbyqxmd.com/read/28821606/flipping-a-citrate-switch-on-liver-cancer-cells
#9
Jeffrey M Peters
Energy homeostasis and oncogenic signaling are critical determinants of the growth of human liver cancer cells, providing a strong rationale to elucidate the regulatory mechanisms for these systems. A new study reports that loss of solute carrier family 13 member 5, which transports citrate across cell membranes, halts liver cancer cell growth by altering both energy production and mammalian target of rapamycin signaling in human liver cancer cell lines and in both an in vitro and in vivo model of liver tumors, suggesting a new target for liver cancer chemoprevention and/or chemotherapy...
August 18, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/28820635/effects-of-autologous-cytokine-induced-killer-cells-infusion-in-colorectal-cancer-patients-a-prospective-study
#10
Hao Peng, Meng Yao, Hongwei Fan, Liwei Song, Jinwen Sun, Zheng Zhou, Yunfeng Du, Keyu Lu, Tao Li, Aiguo Yin, Jianhua Xu, Shidong Wei
AIM: To evaluate the efficacy and safety of postoperative adjuvant immunotherapy with cytokine-induced killer (CIK) cells in combination with chemotherapy (CT) in colorectal cancer (CRC) patients. MATERIALS AND METHODS: A total of 46 patients were randomly assigned to either group 1 (control group) or group 2 (CIK group) using blocked randomization. Both groups received the FOLFOX4 (5-fluorouridine, leucovorin, and oxaliplatin) CT. In the CIK group, patients were given CIK cell infusion after FOLFOX4 CT...
August 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28820570/engineering-of-micro-to-nano-structured-3d-printed-drug-releasing-titanium-implants-for-enhanced-osseointegration-and-localized-delivery-of-anticancer-drugs
#11
Shaheer Maher, Gagandeep Kaur, Luis Lima-Marques, Andreas Evdokiou, Dusan Losic
Primary and secondary bone cancers are major causes of pathological bone fractures and their treatment through implant fixation and conventional chemotherapy has many limitations. These implants may suffer from poor osseointegration and their rejection is causing repeated surgery, patient's suffering and extensive expenses. On the other hand, there are severe systemic adverse effects of toxic chemotherapeutics administrated using conventional drug delivery. In this paper to address these two problems we present new type of localized drug-releasing titanium implants with enhanced implants' bio-integration and drug release capabilities that could provide high concentration of toxic anticancer drugs locally to treat bone cancers...
August 18, 2017: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/28820525/the-content-validity-of-a-chemotherapy-induced-peripheral-neuropathy-patient-reported-outcome-measure
#12
Ellen M Lavoie Smith, Rylie Haupt, James P Kelly, Deborah Lee, Grace Kanzawa-Lee, Robert Knoerl, Celia Bridges, Paola Alberti, Nusara Prasertsri, Clare Donohoe
PURPOSE/OBJECTIVES: To test the content validity of a 16-item version of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20). 
. RESEARCH APPROACH: Cross-sectional, prospective, qualitative design. 
. SETTING: Six outpatient oncology clinics within the University of Michigan Health System's comprehensive cancer center in Ann Arbor. 
...
September 1, 2017: Oncology Nursing Forum
https://www.readbyqxmd.com/read/28820513/predictors-of-unplanned-hospitalizations-in-patients-with-nonmetastatic-lung-cancer-during-chemotherapy
#13
Kristen L Fessele, Matthew J Hayat, Robert L Atkins
PURPOSE/OBJECTIVES: To determine predictors of unplanned hospitalizations in patients with lung cancer to receive chemotherapy in the outpatient setting and examine the potential financial burden of these events.
. DESIGN: Retrospective, longitudinal cohort study.
. SETTING: The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database.
. SAMPLE: Of 104,388 incident cases of lung cancer diagnosed from 2005-2009, 2,457 cases of patients with lung cancer who received outpatient chemotherapy were identified...
September 1, 2017: Oncology Nursing Forum
https://www.readbyqxmd.com/read/28820390/small-molecule-inhibitors-of-dna-pk-for-tumor-sensitization-to-anticancer-therapy
#14
M Pospisilova, M Seifrtova, M Rezacova
The most sensitive cell structure - a DNA molecule, is the common target of cancer therapy. DNA damage response (controlled by enzymes from the phosphatidylinositol 3-kinase-related kinases family - PIKK) presents many encouraging targets for improving both conventional cytotoxic anticancer therapy and individualized monotherapy. DNA-dependent protein kinase (DNA-PK) is a member of the PIKK superfamily and plays an important role in the detection and repair of DNA double-strand breaks via the non-homologous end-joining pathway...
June 2017: Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society
https://www.readbyqxmd.com/read/28820270/second-line-treatment-options-for-pancreatic-cancer
#15
Frank C Passero, Muhammad Wasif Saif
ABTRACT Introduction: Patients with advanced pancreatic cancer (APC) refractory to first-line therapy have a dismal prognosis and limited therapeutic options, with only one option consisting of nanoliposomal irinotecan in combination with fluorouracil and folinic acid which was approved by FDA based upon results of the phase III NAPOLI-1 study. Areas covered: We performed a literature search for relevant published clinical trials, abstracts of trials in progress and ongoing or planned trials for the second line treatment of APC using Pubmed...
August 18, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28820055/an-update-on-circumventing-multidrug-resistance-in-cancer-by-targeting-p-glycoprotein
#16
Xiaoqian Yang, Xiaoduan Li, Zhenfeng Duan, Xipeng Wang
BACKGROUND: The ultimate emergence of multidrug resistance remains a severe limitation of chemotherapy treatment for patients with cancer. The best-characterized cause of drug resistance involves the overexpression of P-glycoprotein (Pgp), which decreases the intracellular accumulation of chemotherapeutic agents in drug-resistant cancer cells. Thus, Pgp has become an attractive potential target for treating chemotherapy-resistant cancer, butthe outcomes of using chemotherapy in combination with Pgp inhibitors in clinical trials to date have been disappointing...
June 22, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28819769/disparities-in-breast-cancer-private-patients-have-better-outcomes-than-public-patients
#17
W C Coetzee, J P Apffelstaedt, T Zeeman, M Du Plessis
INTRODUCTION: Different outcomes in breast cancer have been reported for low and high socio-economic groups. We present data quantifying disparities between South African public and private patients. METHODS: Records of 240 consecutive patients treated in 2008 in a public versus 97 patients in a private health facility were reviewed for demographic and oncologic data. RESULTS: The average of patients was 56.2 versus 51.9 years (p = 0.032)...
August 17, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28819759/melatonin-increases-the-effect-of-5-fluorouracil-based-chemotherapy-in-human-colorectal-adenocarcinoma-cells-in-vitro
#18
Roberto Pariente, Ignacio Bejarano, Ana Beatriz Rodríguez, José Antonio Pariente, Javier Espino
Melatonin has antitumor activity via several mechanisms including its anti-proliferative and pro-apoptotic effects. Moreover, it has been proven that melatonin in combination with chemotherapeutic agents enhances chemotherapy-triggered apoptosis in several types of cancer. Therefore, this study was intended to evaluate whether melatonin is able to strengthen the anti-cancer potential of different chemotherapeutic drugs in human colorectal adenocarcinoma HT-29 cells. We found that treatment with 20 µM cisplatin (CIS) or 1 mM 5-fluorouracil (5-FU) for 72 h induced a decrease in HT-29 cell viability...
August 17, 2017: Molecular and Cellular Biochemistry
https://www.readbyqxmd.com/read/28819727/abiraterone-acetate-a-review-in-metastatic-castration-resistant-prostrate-cancer
#19
Lesley J Scott
Oral abiraterone acetate (Zytiga(®)) is a selective inhibitor of CYP17 and thereby inhibits androgen biosynthesis, with androgen signalling crucial in the progression from primary to metastatic prostate cancer (PC) and subsequently, in the development of metastatic castration-resistant PC (mCRPC). In large phase 3 trials and in the clinical practice setting, oral abiraterone acetate in combination with prednisone was an effective treatment and had an acceptable, manageable tolerability and safety profile in chemotherapy-naive and docetaxel-experienced men with mCRPC...
August 17, 2017: Drugs
https://www.readbyqxmd.com/read/28819699/cudc-907-a-dual-hdac-and-pi3k-inhibitor-reverses-platinum-drug-resistance
#20
Kenneth K W To, Li-Wu Fu
Platinum (Pt)-based anticancer drugs are the mainstay of treatment for solid cancers. However, resistance to Pt drugs develops rapidly, which can be caused by overexpression of multidrug resistance transporters and activation of DNA repair. CUDC-907 is a potent molecular targeted anticancer agent, rationally designed to simultaneously inhibit histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K). We investigated the potentiation effect of CUDC-907 on Pt drugs in resistant cancer cells. ABCC2 stably-transfected HEK293 cells and two pairs of parental and Pt-resistant cancer cell lines were used to test for the circumvention of resistance by CUDC-907...
August 17, 2017: Investigational New Drugs
keyword
keyword
11110
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"